Trial Profile
A real-world study evaluating safety and efficacy of disease modifying therapies (fingolimod, dimethylfumarate, teriflunomide, natalizumab and alemtuzumab) in Belgian multiple sclerosis patients:The BELTRIMS registry
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 29 Oct 2018
Price :
$35
*
At a glance
- Drugs Alemtuzumab (Primary) ; Dimethyl fumarate (Primary) ; Fingolimod (Primary) ; Natalizumab (Primary) ; Teriflunomide (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions; Therapeutic Use
- 29 Oct 2018 New trial record
- 12 Oct 2018 Study design presented at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis